Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone

Yi-Bin ChenDepartment of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USACorrespondence[email protected]

Ephraim P. HochbergDepartment of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA

Yang FengDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA

Donna NeubergDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA

Bhupendra RawalDepartment of Biostatistics, Moffit Cancer Center, Tampa, FL, USA

Gabriela MotyckovaDivision of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA

David C. FisherDivision of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA

Steven L. McafeeDepartment of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA

Thomas R. SpitzerDepartment of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA

Ann S. LacasceDivision of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA

Your download is now in progress and you may close this window